MedTrace Logo

The Role of Vitamin D3 in Pediatric Bronchiectasis Severity

NCT04411901 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-06-02

No results posted yet for this study

Summary

Vitamin D3 therapy was effective in decreasing the frequency of pulmonary exacerbations and preserving lung functions , thereby improving the disease severity even more in non CF than CF bronchiectasis patients

Conditions

  • Cystic Fibrosis and Non CF Bronchiectasis

Interventions

DRUG

Cholecalciferol (vitaminD3)

Theraputic vitamin D3 for CF and non CF bronchiectasis children

Sponsors & Collaborators

  • Heba Omara

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-01
Primary Completion
2018-09-06
Completion
2019-03-20

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04411901 on ClinicalTrials.gov